The status of the matrix metalloproteinase system in patients with community-acquired pneumonia
https://doi.org/10.34215/1609-1175-2026-2-41-44
Abstract
Objective: To assess the status of the matrix metalloproteinase (MMP) system in patients with severe community-acquired pneumonia (CAP) based on serum levels of MMP-2, MMP-7, and the MMP-9/TIMP-1 and MMP-9/TIMP-2 complexes, as well as to monitor these levels over time.
Materials and methods. An open-label observational comparative study was conducted. The main cohort included 55 patients with severe CAP. The control group consisted of ten normally healthy volunteers. Venous blood samples were collected on days 1, 3, 6, 9, and 12 (in the control group, a single sample was collected). Marker concentrations were determined using the ELISA method. Statistical analysis was performed using SPSS 25.0.
Results. Dynamic monitoring revealed no clear, single-directional dynamics for the MMP-2 and MMP-9/TIMP complexes. However, MMP-7 levels decreased by day 3 and subsequently increased. This may correspond to a shift between the inflammatory and reparative phases during the fluctuating progression of severe CAP.
Conclusion. Serum MMP-7 levels are a promising marker of CAP severity; their dynamics correlate with early protease-dependent remodeling and worsening lung barrier dysfunction.
About the Authors
P. A. Knyazenko
Pacific State Medical University; Vladivostok Clinical Hospital No. 1
Russian Federation
Russian Federation
Vladivostok
E. V. Markelova
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
A. V. Kostyushko
Pacific State Medical University
Russian Federation
Russian Federation
Anna V. Kostyushko - Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Normal and Pathological Physiology.
2 Ostryakova ave., Vladivostok, 690002
E. V. Bakhtina
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
Ya. A. Khlystun
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
References
1. Anderzhanova AA, Melyoshkina YuA. Community-acquired pneumonia: diagnosis, treatment approaches. The Clinician. 2019;13(1–2):55–64. (In Russ.). doi 10.17650/1818-8338-2019-13-1-2-55-64
2. Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, van der Poll T. Pneumonia. Nat Rev Dis Primers. 2021;7(1):25. doi: 10.1038/s41572-021-00259-0
3. Tsoumani E, Carter JA, Salomonsson S, Stephens JM, Bencina G. Clinical, economic, and humanistic burden of communityacquired pneumonia in Europe: a systematic literature review. Expert Rev Vaccines. 2023;22(1):876–884. doi: 10.1080/14760584.2023.2261785
4. Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 2006;17(4):217–223. doi: 10.1016/j.cytogfr.2006.04.001
5. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K. Diagnosis and treatment of adults with communityacquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45– e67. doi: 10.1164/rccm.201908-1581ST
6. Aghasafari P, George U, Pidaparti R. A review of inflammatory mechanism in airway diseases. Inflamm Res. 2019;68:59–74. doi: 10.1007/s00011-018-1191-2
7. Swenson KE, Swenson ER. Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury. Crit Care Clin. 2021;37(4):749–776. doi: 10.1016/j.ccc.2021.05.003
8. Zhou J, Fang S, Zhu J, Su Y, Zhou H. Multiple Organ Dysfunction Syndrome Associated With Pneumonia: A Retrospective Study With a Focus on Respiratory Failure. Br J Hosp Med. 2025;86(5):1–13.
9. Viasus D, Del Rio-Pertuz G, Simonetti AF, Garcia-Vidal C, Acosta-Reyes J, Garavito A, Carratalà J. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect. 2016;72(3):273–282. doi: 10.1016/j.jinf.2016.01.002
10. Fan W, Gui B, Zhou X, Li L, Chen H. A narrative review on lung injury: Mechanisms, biomarkers, and monitoring. Crit Care. 2024;28(1):352. doi: 10.1186/s13054-024-05149-x
11. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3): 562–573. doi: 10.1016/j.cardiores.2005.12.002
12. Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov. 2014;13:904–927. doi: 10.1038/nrd4390
13. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002;37(6):375–536. doi: 10.1080/10409230290771546
14. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55–71. doi: 10.1016/j.bbamcr.2010.01.003
Review
For citations:
Knyazenko P.A., Markelova E.V., Kostyushko A.V., Bakhtina E.V., Khlystun Ya.A. The status of the matrix metalloproteinase system in patients with community-acquired pneumonia. Pacific Medical Journal. 2026;(2):41-44. (In Russ.) https://doi.org/10.34215/1609-1175-2026-2-41-44
Views:
44
JATS XML
Email this article 